Publication: Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics
Issued Date
2015-08-19
Resource Type
ISSN
15390829
15344827
15344827
Other identifier(s)
2-s2.0-84935853947
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Diabetes Reports. Vol.15, No.8 (2015)
Suggested Citation
Pornpoj Pramyothin, Lalita Khaodhiar Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics. Current Diabetes Reports. Vol.15, No.8 (2015). doi:10.1007/s11892-015-0623-4 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36348
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics
Author(s)
Other Contributor(s)
Abstract
© 2015, Springer Science+Business Media New York. Youth receiving treatment with antipsychotics are particularly susceptible to weight gain, type 2 diabetes (T2D), and associated metabolic disorders, which is directly associated with excess morbidity and mortality in this vulnerable population. The risk of T2D is 2- to 3-fold that of the general population, starts early in the course of treatment, and reflects the effects of weight gain in conjunction with direct effects of antipsychotics on the hypothalamus, pancreatic beta cells, and insulin-sensitive peripheral tissues. Close monitoring with early intervention through lifestyle intervention, switching away from antipsychotics with deleterious metabolic effects, and adjunctive treatment with metformin are modalities available to mitigate weight gain and improve cardiometabolic health in these patients. Despite rapidly advancing knowledge in the field, patient’s access to metabolic screening and quality care remains limited. Efforts must be made to broaden reach of early cardiometabolic intervention among these patients in order to avert serious cardiovascular disease burden in the future.